Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference

Rhea-AI Summary

Myriad Genetics (NASDAQ: MYGN) will present 11 new research studies at the National Society of Genetic Counselors 44th Annual Conference on Nov. 7–8, 2025, highlighting oncology and reproductive genetic testing advances.

Featured products include MyRisk Hereditary Cancer Test, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen, and Foresight Carrier Screen. Myriad will exhibit at booth #317 and share poster presentations on topics such as RNA analysis for VUS interpretation, fetal fraction amplification for early cfDNA screening, prenatal cfDNA detecting maternal colorectal cancer, automated FXN repeat detection, and genetics education and recontact workflows.

SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and reproductive genetic testing at the National Society of Genetic Counselors (NSGC) 44^th Annual Conference. Myriad’s MyRisk^® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel^® Prenatal Screen and Foresight^® Carrier Screen are among the products included in the new studies to be shared.

“The data we’re presenting at NSGC demonstrates our ongoing commitment to advancing scientific research aimed at improving patient outcomes and delivering innovative products that provide timely, data-driven, actionable insights to inform more personalized patient care,” said Katie Johansen Taber, PhD, Vice President, Clinical Product Research & Partnerships, Myriad Genetics. “We’re excited to share this research with the genetic counseling community and to continue collaborating to help make genetic testing more accessible for all patients.”

Myriad’s latest innovations and support services will be on display at booth #317 and through a series of poster presentations throughout the conference.

Myriad’s presentation schedule
Friday, Nov. 7, 2025, at 5:15pm PT

• Poster #CAN103: RNA analysis from residual blood aids the interpretation of Variant of Uncertain Significance (VUS) identified in individuals undergoing hereditary cancer genetic testing
• Poster #GENT253: Fetal fraction amplification yields sufficient fetal fraction to enable cfDNA screening with a low screen-failure rate between 8-10 weeks gestation
• Poster #PRE365: Provider & patient uptake of prenatal cfDNA screening at an earlier gestational age
• Poster #PRE363: Prenatal cell-free DNA screening helps uncover maternal colorectal cancer: a case study
• Poster #GENT245: High-throughput, automated detection of FXN repeat expansions using repeat primed PCR followed by capillary electrophoresis
• Poster #PRE385: From concept to care: the evolution of a genetic screening report through clinical and design collaboration
• Poster #CAN083: The spectrum of germline hereditary cancer mutations within a laboratory-based research registry
• Poster #EDU161: Shaping the future: Evolving a field-based laboratory rotation to meet the needs of genetic counseling students
• Poster #EDU159: Genetic counseling student interest in GC roles in an industry rotation setting
  

Saturday, Nov. 8, 2025, at 5:00pm PT

• Poster #ASD018: Leveraging a longitudinal genomics platform to recontact patients eligible for Hereditary Cancer Genetic Testing
• Poster #PRO394: Professional development for seasoned genetic counselors: Moving from clinical expertise to leadership excellence

For more information about Myriad’s presence at NSGC, please visit: myriad.com/nsgc/. Updates will also be shared across Myriad’s LinkedIn and X channels throughout the conference.

About Myriad Genetics 
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the company’s ongoing commitment to scientific research and collaborations aimed at improving patient outcomes and expanding access to genetic testing. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. 

Investor Contact 
Matt Scalo 
(801) 584-3532 
IR@myriad.com 

Media Contact 
Kate Schraml
(224) 875-4493
PR@myriad.com  

FAQ

What will Myriad Genetics present at the NSGC 44th Annual Conference on Nov. 7–8, 2025 (MYGN)?

Myriad will present 11 research studies on oncology and reproductive genetic testing and exhibit at booth #317.

Which Myriad tests are included in the NSGC 2025 presentations (MYGN)?

Presentations reference MyRisk hereditary cancer, FirstGene multiple prenatal, Prequel prenatal, and Foresight carrier tests.

When and where are Myriad poster presentations scheduled at NSGC 2025 (MYGN)?

Posters are scheduled on Friday, Nov. 7, 2025 at 5:15pm PT and Saturday, Nov. 8, 2025 at 5:00pm PT during the conference.

Which Myriad poster covers early cfDNA screening success at NSGC 2025 (MYGN)?

Poster GENT253 reports fetal fraction amplification enabling cfDNA screening with a low screen-failure rate between 8–10 weeks gestation.

Is Myriad sharing research on interpreting variants of uncertain significance (VUS) at NSGC 2025 (MYGN)?

Yes; Poster CAN103 covers RNA analysis from residual blood to aid VUS interpretation in hereditary cancer testing.

Where can investors and clinicians find updates from Myriad at the NSGC conference (MYGN)?

Updates will be posted at myriad.com/nsgc and on Myriad’s LinkedIn and X channels throughout the conference.